{"analyses":[{"ciLowerLimit":"0.47","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.66","estimateComment":"Regression, Cox method","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","pValueComment":"One-sided p-value based on log-rank test stratified by ECOG performance status, geographic region, and prior history of pelvic radiation.","paramType":"Hazard Ratio (HR)","paramValue":"0.56","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","spread":"5.7","upperLimit":"7.6","value":"7.2"},{"groupId":"OG001","lowerLimit":"3.6","spread":"3.6","upperLimit":"4.2","value":"3.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"416"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression, as determined by Blinded Independent Central Review (BICR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeter \\[mm\\]) in the sum of diameter of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Endometrial cancer (EC) received lenvatinib 20 milligrams (mg) orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study","id":"OG000","title":"Lenvatinib 20 mg + Pembrolizumab 200 mg"},{"description":"Participants with EC received either doxorubicin 60 milligrams per square meter (mg/m\\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle. Participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\\^2 doxorubicin, a maximum dose of paclitaxel per standard of care, or until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.","id":"OG001","title":"Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"Analysis population consisted of ITT population which included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 27 months","title":"PFS Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on BICR in All-comer Participants","type":"PRIMARY","unitOfMeasure":"Months"}